E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
Osteoarthritis (OA) is a degenerative joint disease that can affect any joint in the body, including the hips |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Musculoskeletal Diseases [C05] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10020108 |
E.1.2 | Term | Hips osteoarthritis |
E.1.2 | System Organ Class | 100000004859 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this trial is to compare longitudinal average mean pain scores over 6 months in people with hip osteoarthritis between those receiving best current treatment in addition to a steroid and local anesthetic injection with those receiving best current treatment alone. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives of this trial are: To investigate whether a steroid and local anaesthetic injection and best current treatment is clinically effective at reducing symptoms and improving function compared to best current treatment alone in people with moderate to severe hip pain.
To investigate whether a steroid and local anaesthetic injection and best current treatment is effective at reducing symptoms and improving function compared to a local anaesthetic injection and best current treatment in people with moderate to severe hip pain.
To investigate whether a steroid and local anaesthetic injection and best current treatment is cost effective compared to best current treatment alone in people with moderate to severe hip pain, and whether it leads to a reduction in health care resource use or work absence over 6 months.
To explore, in an interview study, the acceptability and impact of hip injections for people with moderate to severe hip pain.
To explore, in an i |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
There are 2 phases to a linked qualitative study. The objective of phase 1 is:
To explore, in an interview study, the acceptability and impact of hip injections for people with moderate to severe hip pain.
To explore, in an interview study, the experiences of patients living with hip OA
The objective of the optional phase 2 qualitative study is:
If recruitment is lower than anticipated, a linked interview study will explore reasons for non-participation in the trial and perceptions of recruitment processes with the aim of identifying modifiable barriers to recruitment. |
|
E.3 | Principal inclusion criteria |
1. Male or female aged ≥ 40 years 2. A clinical diagnosis of unilateral or bilateral hip OA, and confirmed on plain radiography within the last 2 years, as made by a trained clinician in the musculoskeletal service 3. Moderate to severe current hip pain (a score of 4 or more on a 0-10 numeric rating scale) 4. Symptom duration of episode of at least 6 weeks 5. Hip pain occuring on most days of the last month 6. Informed written consent provided by the patient |
|
E.4 | Principal exclusion criteria |
Participants with the following characteristics are ineligible for the trial: 1. Hip pain due to other disorders (e.g. trochanteric bursitis, avascular necrosis, pain referred from back) 2. Intra-articular corticosteroid injection into the affected hip or ipsilateral trochanteric bursa injection within the proceding 3 months 3. Any previous surgery on the affected hip 4. Clinical suspicion of local or systemic sepsis or infection 5. Current or previous infection of the affected hip 6. Significant trauma to the affected hip requiring immobilisation in the previous 3 months 7. Unwillingness to undergo study interventions 8. Unable to understand and complete self report questionnaires written (or spoken) in English 9. Significant illness (known or suspected) including, but not limited to: - inflammatory joint disease (e.g rheumatoid arthritis, seronegative spondyloarthropathy (ankylosing spondylitis, psoriatic arthritis, reactive arthritis, inflammatory-bowel disease associated with inflammatory arthritis)) - polymyalgia rheumatica or other condition requiring regular oral steroid use - malignancy (where malignancy is thought to be causing hip pain eg. suspected bony metastases) - any other severe medical illness which in the opinion of the local principal investigator (or other authorised clinical delegate) precludes trial participation 10. Pregnant or lactating females 11. Receiving anticoagulants (warfarin, dabigatran, rivaroxaban, low molecular weight heparin or apixaban) 12. Any history of hypersensitivity to triamcinolone acetonide or 1% lidocaine hydrochloride or any of their excipients (1N Hydrochloric Acid QS, 1N Sodium Hydroxide QS, Benzyl alcohol. Polysorbate 80, Sodium carboxymethylcellulose and Sodium chloride). 13. Contraindications to use of local anasesthetic: Complete heart block and hypovolaemia |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary outcome measure for this study is severity of current hip pain as measured by a 0-10 Numerical Rating Scale (NRS). |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Participants will be followed up 2 weeks, 2 months, 4 months and 6 months after baseline. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | Yes |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | Yes |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.1.7.1 | Other trial design description |
A randomised, clinical, single blind, three-arm, parallel group pragmatic trial |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the trial is defined as the collection of the last data item for the last participant to be randomised. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 2 |
E.8.9.1 | In the Member State concerned days | 1 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 2 |
E.8.9.2 | In all countries concerned by the trial days | 1 |